Logo
Please rotate your device

Landscape orientation recommended.

Menu

No results found.

SUS
Surgical Science Sweden AB (publ) – STO
Weekly Share Price & Valuation Overview
Market Overview
Open
101.0000
Close
99.9000
High
101.9000
Low
97.5000
Trend
0.43865

Surgical Science Sweden AB (publ)

Sweden • STO - Nasdaq Stockholm • SUS • Currency: SEK

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator that provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides a high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a state-of-the-art training system that prepares students for the operating room. In addition, the company offers PELVIC Mentor simulator provides anatomy and pelvic exam training; Perc Mentor suite for image-guided interventions; RobotiX Mentor for practice the motor and cognitive skills for surgeons; Simball Box, which combines with digitally collected metrics into a powerful training tool; Spine Mentor, a training simulator for minimal invasive spine surgery; TEE Express, designed to teach Trans-Esophageal Echocardiography procedure using a TEE probe; TraumaVR, an ultimate mix of manikin and VR simulation; and Ultrasound Mentor for ultrasound training with multiple medical specialties. Surgical Science AB was incorporated in 1997 and is based in Gothenburg, Sweden.

Key strengths
  • Growth + profitability: double-digit revenue and profit margins.
  • Healthy operating margin (≥15%) indicates efficient core operations.
  • High gross margin (≥35%) suggests strong pricing power or cost control.
  • Double-digit profit margin (≥10%) supports robust bottom-line economics.
  • Revenue growth ≥10% indicates solid top-line momentum.
  • Earnings growth ≥10% supports improving profitability trajectory.
  • Quick ratio ≥1.0 indicates obligations can be met without inventory.
  • Net cash balance sheet provides flexibility for downturns and investment.
Scale & Structure Core size and share structure. TTM values unless noted. “Estimated” where reconciled from per-share × shares.
Market Cap Total equity value of the company (share price × shares outstanding).
SEK 5.02B
Enterprise Value Operating value: market cap + total debt − cash.
SEK 4.41B
Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
SEK 946.53M
Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
SEK 647.17M
EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
SEK 196.16M
Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
SEK 18.55
EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
2.76
Shares Outstanding
51.03M
Float Shares
43.49M
Implied Shares Outstanding
51.80M
Profitability & Efficiency TTM basis. “Reconciled” = numerator ÷ TTM revenue. Margins reflect latest TTM calculations.
Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
20.12%
EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
20.72%
Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
68.37%
Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
14.91%
ROA Return on assets: net income ÷ total assets.
2.14%
ROE Return on equity: net income ÷ shareholder equity.
3.11%
Growth Growth rates are YoY unless labeled QoQ.
Revenue Growth Strong Year-over-year revenue growth.
33.20%
Earnings Growth (YoY) Strong Year-over-year earnings growth.
39.40%
Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
39.70%
Liquidity & Solvency Balance-sheet health. Debt metrics shown as latest ratios; D/E is a ratio (not %).
Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
2.87
Debt to Equity Total debt ÷ shareholder equity; leverage.
0.04
Total Cash Cash and equivalents.
SEK 612.89M
Total Debt Short + long-term interest-bearing debt.
SEK 1.64M
Net Debt Net Cash Total debt − cash (negative = net cash).
SEK -611.25M
Debt / EBITDA Leverage relative to operating earnings; lower is safer.
0.01
Cash Flow Shown only when internally consistent; margins are TTM.
Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
SEK 103.78M
Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
SEK 44.31M
OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
10.96%
FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
4.68%
Cash Conversion (OpCF/EBITDA)
0.53
Sharemaestro House View
Confidence: 2 Sharemaestro internal conviction (0–3, higher is better). Risk: 3 Sharemaestro internal risk profile (0–3, higher is safer). Operational: 3 Operational quality/consistency (0–3, higher is better). Composite Score: 3 Overall internal composite (0–3, higher is better). Suggested Allocation: 5.00% Indicative portfolio weighting suggestion based on house view.
Structural Insights (experimental)
Ownership & Liquidity
Free Float Proportion of shares available for public trading. 85.2%
Insiders Shares held by company insiders (officers, directors). 25.7%
Institutions Shares held by institutions (funds, pensions). 61.0%
Capital Structure
Potential Dilution Increase in share count if options/convertibles exercise.
1.5%
Net Debt Total debt − cash (negative = net cash).
SEK -611.25M
-64.6% of revenue Net debt relative to revenue — debt load vs business scale.
Resilience Score 0–100 composite of liquidity, leverage and cash conversion; higher is better. If inputs are unavailable, we estimate using proxies (Net debt vs revenue, Cash-to-Debt). It is a guide, not a rating. 78
Methodology Notes
  • Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
  • Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
As of: 2025-08-18 10:12

Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.

AI generated insights not available yet. Sign in to generate the snapshot.